Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment.

导出 LinkOut

翻译打印收藏纠错

第一作者： Maria Vittoria,Dubbini

第一单位： Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

作者： Maria Vittoria,Dubbini ^[1] ; Loredana,De Marco ^[2] ; Licia,Baldi ^[3] ; Luana,Vignolo ^[3] ; Fiorella,Ilariucci ^[1]

作者单位： Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. ^[1] Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. ^[2] Medical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. ^[3]

主题词人类(Humans);肿瘤复发, 局部(Neoplasm Recurrence, Local);免疫轭合物(Immunoconjugates);霍奇金病(Hodgkin Disease);甾类(Steroids)

DOI 10.1080/10428194.2023.2220453

PMID 37282612

发布时间 2024-01-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Leukemia & lymphoma

1497-1499页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment.

Leukemia & lymphoma

相似文献

Leukemia & lymphoma

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Apoptotic colitis secondary to Brentuximab Vedotin: an immune mediated adverse event responsive to steroid treatment.

Leukemia & lymphoma

相似文献

Leukemia & lymphoma

相关期刊

检索历史清除